Drugs / NPT088
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03008161 | Dec 2016 → Feb 2019 | Alzheimer disease | Proclara Biosciences, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NPT088 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03008161 ↗ |
| Modality | Protein / enzyme biologic | “IgG1 Fc-GAIM fusion protein, a recombinant fusion protein” NCT03008161 ↗ |
| Route | Intravenous | “Enrolled patients will receive an intravenous infusion of NPT088 or placebo once a month for six months during this study.” NCT03008161 ↗ |